# A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

> **NCT06335173** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Acumen Pharmaceuticals** · enrollment: 542 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** sabirnetug
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06335173
- **Lead sponsor:** Acumen Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 542 (ACTUAL)
- **Last updated:** 2025-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06335173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06335173, "A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06335173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*